Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | EDNRB | P24530 | 2/20 | 0.36 |
| ▸ | EDNRA | P25101 | 2/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.34 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3528429 | 1.00 | LMNA (0.54) | LMNAGAABCAT1ALDH1A1HSD17B2 | |
| SCHEMBL11778990 | 0.83 | LMNA (0.56) | LMNAGAABCAT1ALDH1A1MAPT | |
| SCHEMBL11781207 | 0.83 | LMNA (0.56) | LMNAGAABCAT1ALDH1A1MAPT | |
| SCHEMBL7029298 | 0.81 | LMNA (0.54) | LMNAGAABCAT1ALDH1A1 | |
| SCHEMBL7029301 | 0.81 | LMNA (0.54) | LMNAGAABCAT1ALDH1A1 | |
| SCHEMBL3527258 | 0.80 | LMNA (0.71) | LMNAGAABCAT1ALDH1A1MMP2 | |
| SCHEMBL3527255 | 0.80 | LMNA (0.71) | LMNAGAABCAT1ALDH1A1MMP2 | |
| SCHEMBL4110091 | 0.79 | LMNA (0.70) | LMNAGAABCAT1ALDH1A1KDM4E | |
| SCHEMBL4972178 | 0.79 | LMNA (0.70) | LMNAGAABCAT1ALDH1A1KDM4E | |
| SCHEMBL7617768 | 0.76 | LMNA (0.61) | LMNAGAABCAT1ALDH1A1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7759366-B2 | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use | SANOFI-AVENTIS (FR) | 2010-07-20 | — | — | US | disclosed |
| US-20090215728-A1 | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use | SANOFI-AVENTIS (FR) | 2009-08-27 | — | — | US | disclosed |
| EP-2061767-A1 | ARYLAMINOARYL-ALKYL-SUBSTITUTED IMIDAZOLIDINE-2,4-DIONES, PROCESSES FOR PREPARING THEM, MEDICAMENTS COMPRISING THESE COMPOUNDS, AND THEIR USE | Sanofi-Aventis (FR) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008017381-A1 | ARYLAMINOARYL-ALKYL-SUBSTITUTED IMIDAZOLIDINE-2,4-DIONES, PROCESSES FOR PREPARING THEM, MEDICAMENTS COMPRISING THESE COMPOUNDS, AND THEIR USE | SANOFI-AVENTIS (FR) | 2008-02-14 | — | — | WO | disclosed |
| EP-1076651-B1 | SUBSTITUTED SULPHONYL CYANAMIDES, METHOD FOR PRODUCING SAME AND THEIR USE AS MEDICAMENT | AVENTIS PHARMA GMBH (DE) | 2005-04-20 | — | — | EP | disclosed |
| US-6573288-B1 | Compounds are inhibitors of the sodium-dependent bicarbonate/chloride ion exchanger which can be used as medicines for the prophylaxis or treatment of a wide range of diseases, for example the treatment and/or prophylaxis of | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-06-03 | — | — | US | disclosed |
| US-6486189-B2 | TREATMENT OR PROPHYLAXIS OF AN ILLNESS CAUSED BY AN ISCHEMIC CONDITION, OR FOR THE TREATMENT OF IMPAIRED RESPIRATORY DRIVE | HOECHST AKTIENGESELLSCHAFT (DE) | 2002-11-26 | — | — | US | disclosed |
| US-20020045761-A1 | Five-membered heterocycles having biphenylsulfonyl substitution, process for their preparation, their use as a medicament or diagnostic, and medicament comprising them | KLEEMANN HEINZ-WERNER (DE) | 2002-04-18 | — | — | US | disclosed |
| US-6335451-B1 | ANTIARRYTHMIA AGENTS, ANTIPROLIFERATIVE AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 2002-01-01 | — | — | US | disclosed |
| EP-1076651-A1 | SUBSTITUTED SULPHONYL CYANAMIDES, METHOD FOR PRODUCING SAME AND THEIR USE AS MEDICAMENT | Aventis Pharma Deutschland GmbH (DE) | 2001-02-21 | — | — | EP | disclosed |
| WO-1999057102-A1 | SUBSTITUTED SULPHONYL CYANAMIDES, METHOD FOR PRODUCING SAME AND THEIR USE AS MEDICAMENT | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 1999-11-11 | — | — | WO | disclosed |
| EP-0855392-A2 | Five-membered heterocycles having biphenylsulphonyl substituents, processes for the preparation thereof, their use as medicaments or diagnostic agent and medicaments containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-07-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215728-A1 | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use | GPR119, GIPR, LIPC | LMNA 815/4885GAA 157/4885BCAT1 1826/4885 |
| US-20020045761-A1 | Five-membered heterocycles having biphenylsulfonyl substitution, process for their preparation, their use as a medicament or diagnostic, and medicament comprising them | BAX, BCL2, TNNI3 | LMNA 230/4885GAA 2799/4885BCAT1 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.